AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03142230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier
Description: The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
Study NCT00883402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEA, CAS
Description: Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
Study NCT01519700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP2006
Description: Eligible patients will be teated with EP2006
Study NCT01519700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Eligible patients will be teated with Filgrastim
Study NCT01024270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT01774734 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly
Study NCT01774734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly
Study NCT01774734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck Strength Exerciser (NSE)
Description: * Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist
Study NCT02553486 — intervention group
Intervention type: OTHER
Intervention: quality of life evaluation
Study NCT03348358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic music
Description: playing rhythmic music during labor
Study NCT03348358 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: No music during labor
Study NCT01399242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certican
Description: Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
Study NCT02389504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Exertional Physical Therapy
Description: By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
Study NCT02389504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exertional Physical Therapy
Description: Standard treadmill running, monitoring heart rate
Study NCT01783951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
Study NCT01514201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01514201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT01514201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT01783951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
Study NCT01783951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
Study NCT01783951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
Study NCT01783951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
Study NCT00389116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gastrograffin
Description: ingestion
Study NCT00389116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: oral water ingestion
Study NCT01112293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1008
Description: GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
Study NCT02838212 — intervention group
Intervention type: DRUG
Intervention: adverse drug reaction
Description: drug-related death
Study NCT06321874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen
Study NCT04226482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Device
Description: Laparoscopic appendectomy using new ultrasonic shears.
Study NCT04226482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Used Device
Description: Laparoscopic appendectomy using reprocessed ultrasonic shears.
Study NCT01807052 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04477577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Parent Intervention
Description: This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
Study NCT04477577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Control
Description: This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
Study NCT00917761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon (Pegasys) (52 weeks)
Description: Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
Study NCT01185873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Repeated oral doses
Study NCT01185873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Repeated oral doses
Study NCT00855088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
Study NCT00855088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
Study NCT00855088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
Study NCT02767427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Wipes
Description: (Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
Study NCT02767427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
Study NCT02885155 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: planned at regular intervals
Study NCT02885155 — intervention group
Intervention type: OTHER
Intervention: Hemodynamic examinations (right cardiac catheterization)
Description: planned at regular intervals
Study NCT01544530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold isotonic fluid and central venous hypothermia catheter
Description: 20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
Study NCT00917761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (Pegasys) (96 weeks)
Description: Peginterferon alfa-2a 180 ug/week sc at week 1-96
Study NCT05510869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally
Description: microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
Study NCT05510869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.
Description: microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
Study NCT05510869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.
Description: small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
Study NCT03062475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention with dietary and exercise recommendation
Description: With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy.
Study NCT00633191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-pseudomonas IgY gargle
Description: Gargle (solution), > 5FKU, every night after toothbrushing, life-long
Study NCT02101502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questioner
Description: Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
Study NCT03602937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renastep
Description: Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
Study NCT04067284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding
Study NCT04067284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Homemade yogurt supplementation
Description: The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
Study NCT04067284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No intervention/ control group
Study NCT03522181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline
Study NCT00917761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon (Pegasys) (48 weeks)
Description: Peginterferon alfa-2a 180 ug/week sc at week 1-48
Study NCT01520376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Visit by a psychiatrist at day-30 and day-180 after discarge
Study NCT02936466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bipolife® group
Description: The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition.
Study NCT01441882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01441882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01441882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01758913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
Study NCT02988830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous Electric Lumbar Stimulation
Study NCT03471507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bonipar
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Study NCT03471507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium topical solution 1.5%
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Study NCT03421873 — intervention group
Intervention type: OTHER
Intervention: 0h/1h hs-cTnT protocol
Description: Implementation of a 0h/1h hs-cTnT protocol in routine care
Study NCT02652351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
Study NCT02489292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
Study NCT00828763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14c}-GSK1349572
Description: HIV-Integrase inhibitor labelled with a carbon 14 marker
Study NCT00300313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 to 20 mg / day
Study NCT00300313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 capsules
Study NCT03018639 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
Study NCT03078894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Zika
Description: Zika Diagnostic test
Study NCT03078894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chikagunya
Description: Chikagunya Diagnostic test
Study NCT03078894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dengue
Description: Dengue Diagnostic test
Study NCT04355546 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
Study NCT01389869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sniffing emotional tears
Description: A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
Study NCT01389869 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sniffing trickled saline
Description: A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
Study NCT01389869 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sniffing fasting plasma
Description: A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
Study NCT01389869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sniffing postprandial plasma
Description: A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
Study NCT01804881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Six week program to address problematic eating
Study NCT01804881 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: Six week program to address problematic eating
Study NCT02316496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab 500mg/m²/ IV infusion, (q2w)
Study NCT02316496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
Study NCT03261219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive ventilation
Description: mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
Study NCT03261219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Physiotherapy Vest (Incourage)
Description: mode of airway clearance using external vibratory vest
Study NCT00546546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early immunosuppressants (azathioprine, methotrexate)
Description: azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
Study NCT02569684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic fibers: oligofructose and inulin
Study NCT02569684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT01770171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
Study NCT01770171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Description: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Study NCT02862873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Study NCT02862873 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal anaesthesia
Study NCT02862873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Study NCT02862873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Study NCT00836186 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy
Description: Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
Study NCT02977858 — intervention group
Intervention type: OTHER
Intervention: Educational practice for HCPs,Dissemination only
Description: Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
Study NCT02977858 — intervention group
Intervention type: OTHER
Intervention: Educational practice for HCPs,Spaced Education
Description: Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
Study NCT03522181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin